Irritable bowel syndrome (IBS) is characterized by abdominal pain and alterations in bowel habits. Several pathogenetic factors, such as altered intestinal motility, visceral hypersensitivity, serotonin system abnormalities and psychic disturbances have been identified. Recently, a pathogenetic role of intestinal microflora has been shown in IBS: viral or bacterial infection can trigger post-infectious IBS; some patients have small intestinal bacterial overgrowth; the composition of patients' enteric flora is altered; and minimal inflammatory changes, consistent with the pro-inflammatory role of bacteria, have been demonstrated. Probiotics may, therefore, offer a rational therapeutic approach to IBS. The data available on the use of probiotics in IBS are still limited and results of controlled clinical trials are contradictory because they have been performed using different species, dosages, treatment durations and end-points for results evaluation. A critical evaluation of the therapeutic role of the various probiotics in IBS is presented in this article.
WilsonSRobertsLRoalfeA: Prevalence of irritable bowel syndrome: A community survey. Br J Clin Pract2004; 54: 495–502.
4.
JailwalaJImperialeTFKroenkeK: Pharmacological treatment of the irritable bowel syndrome: A systematic review of randomized controlled trials. Ann Int Med2000; 133: 136–147.
5.
HalvorsonHSchlettCDRiddleMS: Postinfectious irritable bowel—a meta-analysis. Am J Gastroenterol2006; 101: 1–6.
6.
RodriguezLAGRuigomezA: Increased risk of irritable bowel syndrome after bacterial gastroenteritis: Cohort study. BMJ1999; 318: 565–566.
7.
LinHC: Small intestinal bacterial overgrowth: A framework for understanding irritable bowel syndrome. JAMA2004; 292: 852–858.
8.
WaltersBVannerSJ: Detection of bacterial overgrowth in IBS using the lactulose H2 breath test. Am J Gastroenterol2005; 100: 1566–1570.
9.
BalsariACeccarelliADubiniF: The fecal microbial population in irritable bowel syndrome. Microbiologica1982; 5: 185–194.
10.
SiJMYuYCFanYJ: Intestinal microbiology and quality of life in irritable bowel syndrome. World J Gastroenterol2004; 10: 1802–1805.
11.
MalinenERintillaTKajanderK: Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol2005; 100: 373–382.
12.
MaddenJAJPlummerSSenS: Comparison of the caecal and faecal microflora of healthy subjects and patients with irritable bowel syndrome. Gut2001; 48 (suppl 1): A58.
13.
KoideAYamaguchiTOdakaT: Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. Am J Gastroenterol2000; 95: 1735–1741.
SerraJApzirozFMalageladaJR: Impaired transit and tolerance of intestinal gas in irritable bowel syndrome. Gut2001; 48: 14–19.
16.
SpillerRC: Infection, immune function and functional gut disorders. Clin Gastroenterol Hepatol2004; 2: 445–455.
17.
GweeKACollinsSMReadNW: Increased rectal mucosal expression of interleukin-1 beta in recently acquired post-infectious irritable bowel syndrome. Gut2003; 52: 523–526.
18.
BarbaraGDe GiorgioRDengY: Role of immunologic factors and cycloxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. Gastroenterology2001; 120: 1729–1736.
19.
YoungPCashBD: Probiotic use in irritable bowel syndrome. Curr Gastroenterology Rep2006; 8: 321–326.
20.
DunlopSPHebdenJNaesdalJ: Abnormal intestinal permeability in subgroups of diarrhea predominant irritable bowel syndrome. Am J Gastroenterol2006; 101: 1288–1294.
21.
AttarAFlouriéBRambaudJC: Antibiotic efficacy in intestinal bacterial overgrowth-related chronic diarrhea: A crossover randomized trial. Gastroenterology1999; 117: 794–797.
22.
Di StefanoMMalservisiSVenetoG: Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther2000; 14: 551–556.
23.
PimentelMChowEJLinHC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: A double-blind, randomized, placebo-controlled study. Am J Gastroenterol2003: 98: 412–419.
24.
O'MahonyLMcCarthyJKellyP: A randomized, placebo-controlled, double-blind comparison of the probiotic bacteria Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom response and relationship to cytokines profiles. Gastroenterology2005; 128: 541–550.
25.
KimHJRoqueM VazquezCamilleriM: A randomized controlled trial of a probiotic combination VSL #3 in irritable bowel syndrome with bloating. Neurogastroenterol Motil2005; 17: 687–696.
26.
ButsJPDe KeyserN: Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci2006; 51: 1485–1492.
27.
McFarlandLV: Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol2006; 101: 812–822.
28.
GuslandiMMezziGTestoniPA: Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci2000; 45: 1462–1464.
29.
DalmassoGCottrezImbertV: Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology2006; 131: 1812–1825.
30.
NobaekSJohanssonMLMolinG: Alteration in intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol2000; 95: 1231–1238.
31.
SenSMullanMMParkerTJ: Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci2002; 47: 2615–2620.
32.
NiedzielinKKordeckiHBirkenfeldB: A controlled double-blind, randomized study of the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol2001; 13: 1143–1147.
33.
SaggioroA: Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol2004; 38 (suppl 6): S104–S106.
34.
O'SullivanMAO'MorainCA: Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis2000; 32: 294–301.
35.
BaussermanMMichailS: The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind placebo control trial. J Pediatrics2005; 147: 197–201.
36.
GawronskaADziechciarzPHorvathA: A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther2007; 25: 177–184.
37.
NivENaftaliTHallakR: The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome—a double-blind, placebo-controlled, randomized study. Clin Nutr2005; 24: 925–931.
38.
WhorwellPJAltringerLMorelJ: Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol2006; 101: 1581–1590.
39.
MaupasJLChampemontPDelforgeM: Treatment of irritable bowel syndrome. Double-blind trial of Saccharomyces boulardii. Med Chir Digest1983; 12: 77–79.
40.
BennaniA: Essai randomise de Saccharomyces boulardii dans le traitement des colopathies fonctionnelles. L'Objectif Médical1990; 73: 56–61.
41.
TsuchiyaJBarretoROkuraR: Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis2004; 5: 169–174.
42.
KajanderKHatakkaKPoussaT: A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: A controlled six-month intervention. Aliment Pharmacol Ther2005; 22: 387–394.
43.
PranteraCScribanoMLFalascoG: Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised controlled trial with Lactobacillus GG. Gut2002; 51: 405–409.
44.
SchultzMTimmerAHerfarthH: Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol2004; 4: 5.
45.
BousvarosAGuandaliniSBaldassanoRN: A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis2005; 11: 833–839.
